Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

US FDA approves Bio-Thera Solutions & Hikma Pharma’s Starjemza injection, a biosimilar referencing Stelara injection: Guangzhou Wednesday, May 28, 2025, 17:00 Hrs [IST] Bio-Ther ...

Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...

After one year of Cosentyx treatment, patients who achieved ... disease modifying ability of Cosentyx in psoriasis." Meanwhile, Johnson & Johnson's Stelara is becoming an increasingly popular ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

providing a new first-line biologic treatment option for patients and has been shown as superior to Stelara and Enbrel in trials. Currently, all biologic treatments for psoriasis, including anti ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and ...